Spiracur has initiated a study to evaluate its SNaP Wound Care System to treat lower extremity diabetic, venous and mixed etiology wounds at Cardiff University School of Medicine.
The SNaP Wound Care System’s design eliminates electric or battery power in the healing process and the delivery device is silent and light in weight of 85gms.
The device enables patient to resume their daily activities avoiding exposure of wounds as it is disposable and can fit in patient’s clothing.
The Department of Dermatology and Wound Healing is enrolling up to 45 patients for treatment.
Cardiff University School of Medicine Innovation, Methodologies and Engagement (TIME) Institute for Translation director and study principal investigator Keith Harding and his co-investigators will evaluate the efficacy of the SNaP system for treating difficult to heal lower extremity wounds.
Keith Harding said the fact that results of the US multi-center randomized controlled trial (RCT) show significant improvement in the patient’s quality of life during wound healing is quite promising.
"We are eager to apply this device to patients who are candidates for NPWT devices in the UK, as we believe the SNaP System may redefine how chronic wounds are treated," Harding said.
Spiracur president and CEO Gary Restani said they are very pleased with the final results of the US RCT study, and they look forward to final outcomes from the Cardiff University study.